Ajanta Pharma

Ajanta Pharma
Ajanta Pharma
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
  • Shareholder Return
    724%
  • Sales Growth
    23%
  • Return on Equity
    43 %

Why Super 50

Brothers Yogesh and Rajesh Agrawal have transformed the ailing, legacy business started by their father and uncles in 1973 into a generic drug maker of reckoning by focussing on niche, specialty generic drugs. Ajanta's growth has come from markets like Asia and Africa so far, and the company now plans to create a bigger footprint in the US, the world's largest generic drugs market.



More Stories

X